Putting More Weight on Obesity Trials in Heart Failure.
Curr Heart Fail Rep
; 21(3): 194-202, 2024 06.
Article
em En
| MEDLINE
| ID: mdl-38619690
ABSTRACT
PURPOSE OF REVIEW To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. RECENT FINDINGS:
Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Redução de Peso
/
Insuficiência Cardíaca
/
Obesidade
Limite:
Humans
Idioma:
En
Revista:
Curr Heart Fail Rep
Assunto da revista:
CARDIOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos